When considering the identified drugs that are actively utilised in cardiovascular disease treatment, amrinone is indicated for treatment of congestive heart failure, via inhibition of PDE4, PDE3A/B, and TNF signalling, thereby increasing cAMP/cGMP and calcium influx resulting in increased ionotropic activity [101]. This evidence concerns the gene PDE4A and cardiovascular disorder.